NEXGEL Earnings Call Transcripts
Fiscal Year 2026
-
Revised summary: A strategic review proposes reorganizing to focus on medical devices and biomedical innovation, consolidating assets with Fountainhead Life Sciences, and divesting unprofitable consumer lines. While existing shareholders will be diluted, they may benefit from a stronger, more diversified company and improved financials.
-
A transformative acquisition and partnership have expanded the regenerative medicine portfolio, established a direct sales force, and positioned the platform for rapid growth. Key new products and a unified commercialization strategy are set to drive market expansion.
-
Q1 2026 revenue was $2.65M, down slightly year-over-year, with legacy business flat but showing signs of recovery. The BioNX acquisition is expected to triple annual revenue and be immediately accretive, while integration and new product launches are underway.
-
The acquisition of Celularity's Degenerative Wound segment, backed by Sequence LifeScience, is expected to triple revenue, be immediately accretive, and transform the business into a diversified medical technology platform with strong growth prospects.
Fiscal Year 2025
-
Q3 2025 revenue was flat year-over-year at $2.9M, but gross margin improved to 42.4% and adjusted EBITDA loss narrowed. Strong contract manufacturing and new product launches are expected to drive a record Q4, with full-year revenue guidance of $12M–$12.5M.
-
Significant growth achieved through strategic partnerships, acquisitions, and innovative hydrogel products. Expansion into new markets and product lines, strong revenue growth, and robust R&D pipeline position the company for continued success.
-
Q2 2025 saw revenue double year-over-year to $2.9M, with gross margin rising to 43.6% and narrowing losses. Strong growth in both contract manufacturing and consumer products, expanded partnerships, and new product launches support reaffirmed 2025 guidance for $13M revenue and positive EBITDA.
-
Q1 2025 revenue grew 121% year-over-year to $2.81 million, with gross margin rebounding to 42.4%. Both contract manufacturing and consumer-branded segments expanded, and guidance for $13 million in 2025 revenue and cash flow positivity remains unchanged.
-
Hydrogel technology drives growth across medical, consumer, and contract manufacturing divisions, with strong partnerships, product innovation, and expanding U.S. operations. Margin management and platform-specific marketing support continued revenue growth and a path to profitability.
Fiscal Year 2024
-
Record revenue growth in 2024 was driven by strong performance in both branded consumer products and contract manufacturing, with new partnerships and product launches fueling expansion. Guidance for 2025 targets at least $13 million in revenue and positive EBITDA.
-
The presentation detailed strong revenue growth driven by new product launches, strategic acquisitions, and major partnerships, including nationwide distribution of SilverSeal and an upcoming supply deal with AbbVie. Expansion into new digital and retail platforms is planned, with a focus on achieving cash flow positivity.
-
Record Q3 revenue and gross margin growth driven by branded consumer and contract manufacturing segments, with Silly George and Cintas partnerships fueling momentum. Cash flow positive is within reach, and Q4 is expected to surpass $3 million in revenue.
-
Record Q2 2024 revenue of $1.44M was driven by branded consumer products and the Silly George acquisition, with gross margin rising to 28.5%. Guidance for Q3 and Q4 projects strong growth, and new partnerships and facility expansion position the company for further gains.